483 related articles for article (PubMed ID: 21782201)
1. In vitro photochemical and phototoxicological characterization of major constituents in St. John's Wort (Hypericum perforatum) extracts.
Onoue S; Seto Y; Ochi M; Inoue R; Ito H; Hatano T; Yamada S
Phytochemistry; 2011 Oct; 72(14-15):1814-20. PubMed ID: 21782201
[TBL] [Abstract][Full Text] [Related]
2. [Cellular and molecular effects of the antidepressant hyperforin on brain cells: Review of the literature].
Bouron A; Lorrain E
Encephale; 2014 Apr; 40(2):108-13. PubMed ID: 23816060
[TBL] [Abstract][Full Text] [Related]
3. Investigating the effectiveness of St John's wort herb as an antimicrobial agent against mycobacteria.
Mortensen T; Shen S; Shen F; Walsh MK; Sims RC; Miller CD
Phytother Res; 2012 Sep; 26(9):1327-33. PubMed ID: 22294548
[TBL] [Abstract][Full Text] [Related]
4. Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models.
Butterweck V; Christoffel V; Nahrstedt A; Petereit F; Spengler B; Winterhoff H
Life Sci; 2003 Jun; 73(5):627-39. PubMed ID: 12770617
[TBL] [Abstract][Full Text] [Related]
5. Effects of the antidepressant St. John's wort (Hypericum perforatum) on rat and human vas deferens contractility.
Capasso R; Borrelli F; Montanaro V; Altieri V; Capasso F; Izzo AA
J Urol; 2005 Jun; 173(6):2194-7. PubMed ID: 15879886
[TBL] [Abstract][Full Text] [Related]
6. Aqueous ethanolic extract of St. John's wort (Hypericum perforatum L.) induces growth inhibition and apoptosis in human malignant cells in vitro.
Hostanska K; Reichling J; Bommer S; Weber M; Saller R
Pharmazie; 2002 May; 57(5):323-31. PubMed ID: 12061257
[TBL] [Abstract][Full Text] [Related]
7. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients.
Wurglics M; Schubert-Zsilavecz M
Clin Pharmacokinet; 2006; 45(5):449-68. PubMed ID: 16640452
[TBL] [Abstract][Full Text] [Related]
8. [Hypericin and hyperforin: bioactive components of St. John's Wort (Hypericum perforatum). Their isolation, analysis and study of physiological effect].
Vacek J; Klejdus B; Kubán V
Ceska Slov Farm; 2007 Apr; 56(2):62-6. PubMed ID: 17619301
[TBL] [Abstract][Full Text] [Related]
9. St. John's Wort seed and feverfew flower extracts relieve painful diabetic neuropathy in a rat model of diabetes.
Galeotti N; Maidecchi A; Mattoli L; Burico M; Ghelardini C
Fitoterapia; 2014 Jan; 92():23-33. PubMed ID: 24125916
[TBL] [Abstract][Full Text] [Related]
10. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line.
Tian R; Koyabu N; Morimoto S; Shoyama Y; Ohtani H; Sawada Y
Drug Metab Dispos; 2005 Apr; 33(4):547-54. PubMed ID: 15640377
[TBL] [Abstract][Full Text] [Related]
11. In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs.
Butterweck V; Nahrstedt A; Evans J; Hufeisen S; Rauser L; Savage J; Popadak B; Ernsberger P; Roth BL
Psychopharmacology (Berl); 2002 Jul; 162(2):193-202. PubMed ID: 12110997
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of the antidepressant St. John's wort (hypericum perforatum) on rat bladder contractility in vitro.
Capasso R; Borrelli F; Capasso F; Mascolo N; Izzo AA
Urology; 2004 Jul; 64(1):168-72. PubMed ID: 15245964
[TBL] [Abstract][Full Text] [Related]
13. St. John's wort: role of active compounds for its mechanism of action and efficacy.
Butterweck V; Schmidt M
Wien Med Wochenschr; 2007; 157(13-14):356-61. PubMed ID: 17704987
[TBL] [Abstract][Full Text] [Related]
14. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures.
Komoroski BJ; Zhang S; Cai H; Hutzler JM; Frye R; Tracy TS; Strom SC; Lehmann T; Ang CY; Cui YY; Venkataramanan R
Drug Metab Dispos; 2004 May; 32(5):512-8. PubMed ID: 15100173
[TBL] [Abstract][Full Text] [Related]
15. In vitro binding studies with two hypericum perforatum extracts--hyperforin, hypericin and biapigenin--on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters.
Gobbi M; Moia M; Pirona L; Morizzoni P; Mennini T
Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S45-8. PubMed ID: 11518075
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous determination of total hypericin and hyperforin in St. John's wort extracts by HPLC with electrochemical detection.
Rückert U; Likussar W; Michelitsch A
Phytochem Anal; 2007; 18(3):204-8. PubMed ID: 17500362
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression.
Obach RS
J Pharmacol Exp Ther; 2000 Jul; 294(1):88-95. PubMed ID: 10871299
[TBL] [Abstract][Full Text] [Related]
18. Hypericum perforatum (St John's wort) beyond depression: A therapeutic perspective for pain conditions.
Galeotti N
J Ethnopharmacol; 2017 Mar; 200():136-146. PubMed ID: 28216196
[TBL] [Abstract][Full Text] [Related]
19. Protective effects of St. John's wort extract and its component hyperforin against cytokine-induced cytotoxicity in a pancreatic beta-cell line.
Menegazzi M; Novelli M; Beffy P; D'Aleo V; Tedeschi E; Lupi R; Zoratti E; Marchetti P; Suzuki H; Masiello P
Int J Biochem Cell Biol; 2008; 40(8):1509-21. PubMed ID: 18226577
[TBL] [Abstract][Full Text] [Related]
20. Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort.
Gödtel-Armbrust U; Metzger A; Kroll U; Kelber O; Wojnowski L
Naunyn Schmiedebergs Arch Pharmacol; 2007 Aug; 375(6):377-82. PubMed ID: 17593354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]